Evidence map›Paper›PMID 26925954›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2016

Serologic evidence for hepatitis E virus infection among patients with undifferentiated acute febrile illness in Kibera, Kenya.

N W Furukawa, E H Teshale, L Cosmas, M Ochieng, S Gikunju, B S Fields, J M Montgomery

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

N W FurukawaDepartment of Medicine, University of Washington, Seattle, WA, USA. Electronic address: furukn1@uw.edu.
E H TeshaleDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA.
L CosmasCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.
M OchiengKenya Medical Research Institute, Center for Global Health Research, Nairobi, Kenya.
S GikunjuKenya Medical Research Institute, Center for Global Health Research, Nairobi, Kenya.
B S FieldsCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.
J M MontgomeryCenter for Global Health, Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.
Centers for Disease Control and Prevention · KEKenya Medical Research Institute · KECenters for Disease Control and Prevention · USUniversity of Washington · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundHepatitis E (HEV) is an emerging cause of viral hepatitis mainly transmitted through the fecal-oral route. Residents of the Kibera slum of Nairobi, Kenya are at risk for fecal-orally transmitted infections.

objectiveTo quantify the incidence and prevalence of HEV infection among acute febrile illness (AFI) cases using a population-based infectious disease surveillance network. STUDY

designCross-sectional serum samples from AFI case-patients between 2009 and 2012 were matched to the age and gender distribution of the Kibera population and tested by IgM and IgG enzyme immunoassays (EIA) and nucleic acid testing (NAT). Serum from healthy residents was also tested by EIA.

resultsOf the 482 AFI serum samples tested, 124 (25.7%) and 182 (37.8%) were IgM and IgG reactive, respectively. On multivariate analysis, IgM reactivity was associated with HIV (RR 1.66, 95%CI 1.07, 2.60; p=0.024) while IgG reactivity was associated with increasing age (p<0.001) and HIV (RR 1.93, 95%CI 1.52, 2.46; p<0.001). AFI case-patients were more likely to be IgM (p=0.002) and IgG (p<0.001) reactive compared to healthy residents. The seroincidence by HEV-specific IgM was 84.0 per 1000 person years, however, all 482 samples were negative by NAT.

conclusionsSerologic evidence for HEV in Kibera suggests a high burden of infection, but NAT did not confirm HEV viremia. Additional testing is needed to determine whether EIAs are susceptible to false positivity in undifferentiated AFI populations before their widespread use.

Indexed as

Antibodies, ViralCross-Sectional StudiesFeverHepatitis EHepatitis E virusHumansImmunoglobulin GImmunoglobulin MKenyaSerologic TestsAntibodies, ViralImmunoglobulin GImmunoglobulin MAcute febrile illnessEnzyme immunoassayHepatitis EKenyaKiberaNucleic acid testing

Identifiers

PMID26925954
PMCPMC4861756
OpenAlexW2287986868

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.